Last update Sept. 5, 2014
Inhibitor of tyrosine kinase that is used for treatment of Leukemia and some types of cancer.
Excretion intro breast milk is very low, with no problems reported among breastfed infants from treated mothers.
Concentration in the mother's milk decreases to one half after 9 hours from the last dose which is a property that could be taken advantage of to minimize the dose transfer to the infant if stopping breastfeeding is not desired.
If continuation of safely breastfeeding is desired without assuming high risk for potentially severe side-effects, elimination of total burden of drug should be kept. For this to happen, breastfeeding should be stopped for 10 half-lives (T ½).
It means wait 16 days after the last dose before resuming breastfeeding.
Meanwhile, frequent pump-and-dump is recommended for maintenance of milk production.
We do not have alternatives for Imatinib Mesilate.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM